The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Sun, Wei Chih ^a,b   Hsu, Ping I ^a,b   Yu, Hsien Chung ^a,b,c   Lin, Kung Hung ^a,b   Tsay, Feng Woei ^a,b   Wang, Huay Min ^a,b   Tsai, Tzung Jiun ^a,b   Chen, Wen Chi ^a,b   Lai, Kwok Hung ^a,b   Cheng, Jin Shiung ^a,b  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c MEIHO UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; ANTIVIRUS AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; COMPUTER AIDED DESIGN; DRUG CYTOTOXICITY; FEMALE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HUMAN; INFECTION PREVENTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; OUTCOME ASSESSMENT; PROTOCOL COMPLIANCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; VIRUS REACTIVATION; AGED; BLOOD; GENETICS; HOSPITAL; MIDDLE AGED; NEOPLASMS; REMINDER SYSTEM; VIROLOGY;

HEPATITIS B VIRUS;

AGED; ANTIVIRAL AGENTS; FEMALE; GUIDELINE ADHERENCE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HOSPITALS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; REMINDER SYSTEMS; RETROSPECTIVE STUDIES;

EID: 84922735161     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116978     Document Type: Article

References (46)

1. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ (1975) Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2: 528-530. PMID: 51345
2. Grewal J, Dellinger CA, Yung WK (2007) Fatal reactivation of hepatitis B with temozolomide. N Engl J Med 356: 1591-1592. PMID: 17429098
3. Wands JR, Chura CM, Roll FJ, Maddrey WC (1975) Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68: 105-112. PMID: 1054319
4. Lok AS, Liang RH, Chiu EK,Wong KL, Chan TK, et al. (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100: 182-188. PMID: 1983820
5. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E (1996) Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 78: 2210-2215. PMID: 8918416
6. Lau GK, Liang R, Chiu EK, Lee CK, Lam SK (1997) Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant 19: 795-799. PMID: 9134171
7. Yeo W, Johnson PJ (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43: 209-220. PMID: 16440366
8. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, et al. (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62: 299-307. PMID: 11055239
9. Day FL, Link E, Thursky K, Rischin D (2011) Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J Oncol Pract 7: 141-147. doi: 10.1200/JOP.2010.000133 PMID: 21886492
10. Liang R, Lau GK, Kwong YL (1999) Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 17: 394-398. PMID: 10458258
11. Tsai SH, Dai MS, Yu JC, Ho CL, Chen YC, et al. (2011) Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine. Support Care Cancer 19: 1779-1787. doi: 10.1007/s00520-010-1019-2 PMID: 20927554
12. Yeo W, Lam KC, Zee B, Chan PS, Mo FK, et al. (2004) Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 15: 1661-1666. PMID: 15520068
13. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, et al. (2004) Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90: 1306-1311. PMID: 15054446
14. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, et al. (2008) A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 47: 844-853. doi: 10.1002/hep.22106 PMID: 18302293
15. Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, et al. (2003) Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37: 1320-1328. PMID: 12774010
16. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, et al. (2004) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22: 927-934. PMID: 14990649
17. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, et al. (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148: 519-528. PMID: 18378948
18. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R (2008) Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 15: 89-102. doi: 10.1111/j.1365-2893.2007.00902.x PMID: 18184191
19. Lau GK, Yiu HH, Fong DY, Cheng HC, AuWY, et al. (2003) Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125: 1742-1749. PMID: 14724827
20. Li YH, He YF, Jiang WQ, Wang FH, Lin XB, et al. (2006) Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 106: 1320-1325. PMID: 16470607
21. Kohrt HE, Ouyang DL, Keeffe EB (2006) Systematic review: lamivudine prophylaxis for chemotherapyinduced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 24: 1003-1016. PMID: 16984494
22. Lim LL, Wai CT, Lee YM, Kong HL, Lim R, et al. (2002) Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 16: 1939-1944. PMID: 12390103
23. (2012) EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57: 167-185. doi: 10.1016/j.jhep.2012.02.010 PMID: 22436845
24. Liaw YF KJ, Prratvisuth T, Chan HLY. (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatology Int 6: 531-561.
25. Lok AS, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50: 661-662. doi: 10.1002/ hep.23190 PMID: 19714720
26. Hwang JP, Fisch MJ, Zhang H, Kallen MA, Routbort MJ, et al. (2012) Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract 8: e32-39. doi: 10.1200/JOP.2011.000450 PMID: 23180996
27. Khokhar OS, Farhadi A, McGrail L, Lewis JH (2009) Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation. Chemotherapy 55: 69-75. doi: 10.1159/000183731 PMID: 19077421
28. Lee R, Vu K, Bell CM, Hicks LK (2010) Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol 17: 32-38. PMID: 21151407
29. Tran TT, Rakoski MO, Martin P, Poordad F (2010) Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Ther 31: 240-246. doi: 10.1111/j.1365-2036. 2009.04158.x PMID: 19814747
30. Wang Y, Luo XM, Yang D, Zhang J, Zhuo HY, et al. (2013) Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study. World J Gastroenterol 19: 923-930. doi: 10.3748/ wjg.v19.i6.923 PMID: 23429298
31. Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, et al. (2012) Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 30: 3167-3173. doi: 10.1200/ JCO.2011.40.7510 PMID: 22711851
32. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, et al. (2007) Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 106: 148-155. PMID: 17339159
33. Hwang JP, Fisch MJ, Lok AS, Zhang H, Vierling JM, et al. (2013) Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 13: 534-544. doi: 10.1186/ 1471-2407-13-534 PMID: 24209764
34. LP C, HC Y, PI H, LJ Y, LR L, et al. (2010) Prevalence of Acute Hepatitis and Detection Rate of Viral Hepatitis in Cancer Patients Receiving Chemotherapy: A Single Institution Experience. J Intern Med Taiwan 21: 350-358.
35. Liu CJ, Chen PJ, Chen DS, Kao JH (2013) Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 7: 316-326.
36. Lubel JS, Angus PW (2010) Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 25: 864-871. doi: 10.1111/j.1440-1746.2010.06243.x PMID: 20546439
37. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G (1999) Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 81: 69-74. PMID: 10487614
38. Mok TS, Zee B, Chan AT, Yeo W, Yang WT, et al. (2000) A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer 89: 543-550. PMID: 10931453
39. Yeo W, Chan PK, Hui P, Ho WM, Lam KC, et al. (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70: 553-561. PMID: 12794717
40. Yeo W, Ho WM, Hui P, Chan PK, Lam KC, et al. (2004) Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 88: 209-215. PMID: 15609123
41. Yun J, Kim KH, Kang ES, Gwak GY, Choi MS, et al. (2011) Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer 104: 559-563. doi: 10.1038/bjc.2011.4 PMID: 21285992
42. Long M, Jia W, Li S, Jin L,Wu J, et al. (2011) A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat 127: 705-712. doi: 10.1007/s10549-011-1455-9 PMID: 21445574
43. Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY (2004) Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 24: 540-546. PMID: 15566502
44. Sohn BS, Ahn JH, Jung KH, Ahn SH, Son BH, et al. (2011) Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine. Jpn J Clin Oncol 41: 1059-1066. doi: 10. 1093/jjco/hyr106 PMID: 21821601
45. Hsu C, Tsou HH, Lin SJ,Wang MC, Yao M, et al. (2014) Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology. 59: 2092-2100. doi: 10.1002/hep.26718 PMID: 24002804
46. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, et al. (2013) Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 31: 2765-2772. doi: 10.1200/JCO.2012.48.5938 PMID: 23775967